IL-6 sustains tumor survival, but it also drives production of senescent cells that exhibit a senescence-associated secretory phenotype (20, 21), all of which are predicted to augment dysfunction in CD4+ and CD8+ T cells. This evidence concerns the gene CD4 and neoplasm.